Please complete the CAPTCHA to continue
@chromocyte.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
A. Graham Pockley, Phd is listed as CEO, multimmune GmbH / Emeritus Professor / Cancer Immunobiology & Immunotherapy / Entrepreneur at multimmune GmbH, a company with 2 employees, based in Munich, Bavaria, Germany. AeroLeads shows a work email signal at chromocyte.com and a matched LinkedIn profile for A. Graham Pockley, Phd.
A. Graham Pockley, Phd previously worked as Chief Executive Officer at Multimmune Gmbh and Chief Scientific Officer / Member of Scientific Advisory Board at Radiance Biopharma Inc.. A. Graham Pockley, Phd holds Phd, Immunology (Reproductive) from Sheffield Hallam University.
This section adds company-level context without repeating A. Graham Pockley, Phd's masked contact details.
AeroLeads found 1 current-domain work email signal for A. Graham Pockley, Phd. Compare company email patterns before reaching out.
I am the CEO of multimmune GmbH, Munich, Emeritus Professor of Immunobiology (Nottingham Trent University) and Chief Scientific Officer of Alphageneron Pharmaceuticals Inc. USA, Radiance Biopharma Inc. USA and ExoCellular Diagnostics Inc. USA. I am also the former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK, and was also the Founder and CEO of the flow cytometry resource Chromocyte, the assets of which were sold to Biocompare.My career has focused on the immunobiology of disease, the development of new immunotherapeutic strategies for treating aggressive and 'orphan' cancers, new approaches for analysing and interpreting complex datasets and defining new biomarkers of disease presence, status and response to therapy in patients with cancer.multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics ('theranostics').I have extensive experience at the interface of academia and translational research and can provide a broad range of insights and advice in a number of areas and disciplines:Development of cancer theranosticsImmunoregulatory mechanisms in health and diseaseImmunobiology of heat shock (stress) proteinsCancer ImmunotherapiesMulti-parameter flow cytometryFlow cytometry functional assaysImmunoassay developmentCell-based assays
Listed skills include Flow Cytometry, Immunology, Cell, Cancer, and 46 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Munich Area, Germany
multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells..
Boston, Massachusetts, United States
Radiance Biopharma, Inc. (“Radiance”) is a privately-held immunooncology focussed biotechnology company developing next generation Antibody Drug Conjugates (ADCs). ADCs comprises a monoclonal antibody or monoclonal antibodies that are directed towards target antigens expressed on the cancer cell surface conjugated to a cytotoxic payload via a chemical.
Boston, Massachusetts, United States
We are a pioneering biotechnology company specializing in liquid biopsy-based cancer diagnostic tests. With headquarters in Cambridge, Massachusetts, USA and facilities in Munich, Germany, we are committed to developing and commercializing innovative liquid biopsy-based tests for cancer detection/diagnosis and disease monitoring.The concept of measuring.
Boston, Massachusetts, United States
Alphageneron Pharmaceuticals Inc., USA and multimmune GmbH, Germany signed an Exclusive Worldwide License, and an Option to Purchase Agreement for its immunotherapy and diagnostics platform technology, in 2020.Alphageneron Pharmaceuticals Inc. is developing targeted autologous and allogeneic natural killer cell (‘NK cell’) cancer therapeutics for a number.
Edinburgh, Scotland, United Kingdom
Cytomos is a dynamic early-stage company developing ground-breaking cell analysis systems that can be used alone or alongside conventional technologies such as flow cytometry. Cytomos Dielectric Spectroscopy (CDS) leverages cost-efficient microchip technology, providing streamlined testing strategies and economically viable cell therapies. The technology.
Nottingham, England, United Kingdom
Nottingham, England, United Kingdom
Nottingham, United Kingdom
The John van Geest Cancer Research Centre was established in 2008, as a new research centre within the School of Science and Technology, as a direct result of core funding from the John and Lucille van Geest Foundation. This funding provided a £5m purpose-built Research Centre and a grant support for a team of more than 35 scientists, technicians and.
Nottingham, United Kingdom
Sheffield, England, United Kingdom
Scientific, Biomedical and Pharma Consultancy
Sheffield, United Kingdom
Chromocyte is now a part of Biocompare, the life science's industry’s leading product resource. The Chromocyte mission continues to focus on the Flow Cytometry community with beginners guides, reagents, instruments and training courses.
London, England, United Kingdom
Detroit, Michigan, United States
Sheffield, England, United Kingdom
Title of PhD Thesis: An investigation into the immunoregulatory activities of human placental protein 14 (PP14)
Quick answers generated from the profile data available on this page.
A. Graham Pockley, Phd works for multimmune GmbH.
A. Graham Pockley, Phd is listed as CEO, multimmune GmbH / Emeritus Professor / Cancer Immunobiology & Immunotherapy / Entrepreneur at multimmune GmbH.
AeroLeads has found 1 work email signal at @chromocyte.com for A. Graham Pockley, Phd at multimmune GmbH.
A. Graham Pockley, Phd is based in Munich, Bavaria, Germany while working with multimmune GmbH.
A. Graham Pockley, Phd has worked for Multimmune Gmbh, Radiance Biopharma Inc., Exocellular Diagnostics Inc., Alphageneron Pharmaceuticals, Inc., and Cytomos.
You can use AeroLeads to view verified contact signals for A. Graham Pockley, Phd at multimmune GmbH, including work email, phone, and LinkedIn data when available.
A. Graham Pockley, Phd holds Phd, Immunology (Reproductive) from Sheffield Hallam University.
A. Graham Pockley, Phd is listed with skills including Flow Cytometry, Immunology, Cell, Cancer, Life Sciences, Assay Development, Science, and Molecular Biology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts